WO2005059123A3 - Pp2a/bgamma subunits, modulators thereof, and their uses in the treatment of mental disorders - Google Patents

Pp2a/bgamma subunits, modulators thereof, and their uses in the treatment of mental disorders Download PDF

Info

Publication number
WO2005059123A3
WO2005059123A3 PCT/EP2004/053512 EP2004053512W WO2005059123A3 WO 2005059123 A3 WO2005059123 A3 WO 2005059123A3 EP 2004053512 W EP2004053512 W EP 2004053512W WO 2005059123 A3 WO2005059123 A3 WO 2005059123A3
Authority
WO
WIPO (PCT)
Prior art keywords
subunits
modulators
mental disorders
pp2a
bgamma
Prior art date
Application number
PCT/EP2004/053512
Other languages
French (fr)
Other versions
WO2005059123A2 (en
Inventor
Ilya Chumakov
Pascale Grel
Laurent Cavarec
Original Assignee
Ares Trading Sa
Ilya Chumakov
Pascale Grel
Laurent Cavarec
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ares Trading Sa, Ilya Chumakov, Pascale Grel, Laurent Cavarec filed Critical Ares Trading Sa
Priority to EP04804861A priority Critical patent/EP1694701A2/en
Publication of WO2005059123A2 publication Critical patent/WO2005059123A2/en
Publication of WO2005059123A3 publication Critical patent/WO2005059123A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This invention is in the field of mental disorders such as bipolar disorder, schizophrenia, depression and other mood disorders. More specifically, this invention relates to novel PP2A/BϜ subunits that are generated by alternative splicing events. The invention also relates the use of the novel PP2ABϜ subunits for screening for modulators, and to the use of said modulators for treating said mental disorders.
PCT/EP2004/053512 2003-12-16 2004-12-15 Pp2a/bgamma subunits, modulators thereof, and their uses in the treatment of mental disorders WO2005059123A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP04804861A EP1694701A2 (en) 2003-12-16 2004-12-15 Pp2a/bgamma subunits, modulators thereof, and their uses in the treatment of mental disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03104730.1 2003-12-16
EP03104730 2003-12-16

Publications (2)

Publication Number Publication Date
WO2005059123A2 WO2005059123A2 (en) 2005-06-30
WO2005059123A3 true WO2005059123A3 (en) 2005-11-03

Family

ID=34684599

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/053512 WO2005059123A2 (en) 2003-12-16 2004-12-15 Pp2a/bgamma subunits, modulators thereof, and their uses in the treatment of mental disorders

Country Status (2)

Country Link
EP (1) EP1694701A2 (en)
WO (1) WO2005059123A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001020004A2 (en) * 1999-09-15 2001-03-22 Incyte Genomics, Inc. Protein phosphatase and kinase proteins
WO2004001068A2 (en) * 2002-06-25 2003-12-31 Serono Genetics Institute S.A. Use of pp2a phosphatase modulators in the treatment of mental disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001020004A2 (en) * 1999-09-15 2001-03-22 Incyte Genomics, Inc. Protein phosphatase and kinase proteins
WO2004001068A2 (en) * 2002-06-25 2003-12-31 Serono Genetics Institute S.A. Use of pp2a phosphatase modulators in the treatment of mental disorders

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HU P ET AL: "Molecular Cloning and Mapping of the Brain-Abundant B1gamma Subunit of Protein Phosphatase 2A, PPP2R2C, to Human Chromosome 4p16", GENOMICS, ACADEMIC PRESS, SAN DIEGO, US, vol. 67, no. 1, 1 July 2000 (2000-07-01), pages 83 - 86, XP004439327, ISSN: 0888-7543 *
STRACK STEFAN ET AL: "Brain protein phosphatase 2A: Developmental regulation and distinct cellular and subcellular localization by B subunits", JOURNAL OF COMPARATIVE NEUROLOGY, vol. 392, no. 4, 23 March 1998 (1998-03-23), pages 515 - 527, XP002280061, ISSN: 0021-9967 *
ZOLNIEROWICZ S ET AL: "DIVERSITY IN THE REGULATORY B-SUBUNITS OF PROTEIN PHOSPHATASE 2A: IDENTIFICATION OF A NOVEL ISOFORM HIGHLY EXPRESSED IN BRAIN", BIOCHEMISTRY, AMERICAN CHEMICAL SOCIETY. EASTON, PA, US, vol. 33, no. 39, 1994, pages 11858 - 11867, XP001180134, ISSN: 0006-2960 *

Also Published As

Publication number Publication date
WO2005059123A2 (en) 2005-06-30
EP1694701A2 (en) 2006-08-30

Similar Documents

Publication Publication Date Title
WO2006105516A3 (en) Compositions and methods for diagnosing and treating neuropsychiatric disorders
HUS2100051I1 (en) Compositions and methods of treating cell proliferation disorders
GEP20084550B (en) Substituted morpholine compounds for the treatment of central nervous system disorders
WO2007076070A3 (en) Modulators of muscarinic receptors
TW200503705A (en) 3-amino chroman and 2-amino tetralin derivatives
EA201071245A1 (en) NEW THERAPEUTIC APPROACHES FOR THE TREATMENT OF ALZGEYMER'S DISEASE AND RELATED DISTURBANCES THROUGH MODULATION OF THE STRESS RESPONSE
WO2006023852A3 (en) Modulators of muscarinic receptors
EA200900828A1 (en) COMPOUNDS AND COMPOSITIONS AS AN INHIBITOR ACTIVITY OF THE CANANABINOID RECEPTOR 1
SG10201809390QA (en) Modulators of indoleamine 2,3-dioxygenase and methods of using the same
WO2006091459A3 (en) Compositions and methods for treating vascular permeability
HK1114099A1 (en)
WO2006002262A3 (en) Genes and pathways differentially expressed in bipolar disorder and/or major depressive disorder
HK1092467A1 (en) N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses n-
WO2006058294A3 (en) Modulators of muscarinic receptors
ATE527251T1 (en) BICYCLIC DERIVATIVES AS MODULATORS OF ION CHANNELS
WO2009037707A3 (en) N-phenyl anthranilic acid derivatives and uses thereof
ATE339968T1 (en) USE OF MGLUR5 ANTAGONISTS TO PRODUCE MEDICATIONS FOR THE TREATMENT OF SENSITIVE X SYNDROME, AUTISM AND MENTAL RETARDATION
EA200801302A1 (en) COMPOSITIONS AND METHODS OF TREATMENT OF CNS DISORDERS
ATE542535T1 (en) USE OF AZAPAULLONE FOR THE PREVENTION AND TREATMENT OF PANCREATIC AUTOIMMUNE DISEASES
WO2006080549A3 (en) Method and composition for treating central nervous system disorders
MX2012004548A (en) Novel compositions for preventing and/or treating degenerative disorders of the central nervous system.
ATE459353T1 (en) GABOXADOL USED TO TREAT DEPRESSION AND OTHER AFFECTIVE DISORDERS
MX2007006382A (en) Modulators of muscarinic receptors.
NO20050385L (en) Use of PP2A phosphatase modulators in the treatment of mental disorders
HK1102626A1 (en) Compositions and methods for the treatment and prevention of hyperproliferative diseases

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWE Wipo information: entry into national phase

Ref document number: 2004804861

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004804861

Country of ref document: EP